These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 27622033)

  • 1. MHC class II tetramer analyses in AE37-vaccinated prostate cancer patients reveal vaccine-specific polyfunctional and long-lasting CD4(+) T-cells.
    Anastasopoulou EA; Voutsas IF; Papamichail M; Baxevanis CN; Perez SA
    Oncoimmunology; 2016 Jul; 5(7):e1178439. PubMed ID: 27622033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
    Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
    J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit.
    Anastasopoulou EA; Voutsas IF; Keramitsoglou T; Gouttefangeas C; Kalbacher H; Thanos A; Papamichail M; Perez SA; Baxevanis CN
    Cancer Immunol Immunother; 2015 Sep; 64(9):1123-36. PubMed ID: 26026288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial.
    Perez SA; Anastasopoulou EA; Tzonis P; Gouttefangeas C; Kalbacher H; Papamichail M; Baxevanis CN
    Cancer Immunol Immunother; 2013 Oct; 62(10):1599-608. PubMed ID: 23934022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer.
    Perez SA; Kallinteris NL; Bisias S; Tzonis PK; Georgakopoulou K; Varla-Leftherioti M; Papamichail M; Thanos A; von Hofe E; Baxevanis CN
    Clin Cancer Res; 2010 Jul; 16(13):3495-506. PubMed ID: 20466887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37).
    Mittendorf EA; Holmes JP; Murray JL; von Hofe E; Peoples GE
    Expert Opin Biol Ther; 2009 Jan; 9(1):71-8. PubMed ID: 19063694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
    Holmes JP; Benavides LC; Gates JD; Carmichael MG; Hueman MT; Mittendorf EA; Murray JL; Amin A; Craig D; von Hofe E; Ponniah S; Peoples GE
    J Clin Oncol; 2008 Jul; 26(20):3426-33. PubMed ID: 18612158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines.
    Xu M; Kallinteris NL; von Hofe E
    Vaccine; 2012 Apr; 30(18):2805-10. PubMed ID: 22386748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide.
    Gates JD; Clifton GT; Benavides LC; Sears AK; Carmichael MG; Hueman MT; Holmes JP; Jama YH; Mursal M; Zacharia A; Ciano K; Khoo S; Stojadinovic A; Ponniah S; Peoples GE
    Vaccine; 2010 Nov; 28(47):7476-82. PubMed ID: 20858449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AE37: a HER2-targeted vaccine for the prevention of breast cancer recurrence.
    McCarthy PM; Clifton GT; Vreeland TJ; Adams AM; O'Shea AE; Peoples GE
    Expert Opin Investig Drugs; 2021 Jan; 30(1):5-11. PubMed ID: 33191799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence.
    Mittendorf EA; Ardavanis A; Symanowski J; Murray JL; Shumway NM; Litton JK; Hale DF; Perez SA; Anastasopoulou EA; Pistamaltzian NF; Ponniah S; Baxevanis CN; von Hofe E; Papamichail M; Peoples GE
    Ann Oncol; 2016 Jul; 27(7):1241-8. PubMed ID: 27029708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AE37: a novel T-cell-eliciting vaccine for breast cancer.
    Sears AK; Perez SA; Clifton GT; Benavides LC; Gates JD; Clive KS; Holmes JP; Shumway NM; Van Echo DC; Carmichael MG; Ponniah S; Baxevanis CN; Mittendorf EA; Papamichail M; Peoples GE
    Expert Opin Biol Ther; 2011 Nov; 11(11):1543-50. PubMed ID: 21895539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.
    Walker EB; Haley D; Miller W; Floyd K; Wisner KP; Sanjuan N; Maecker H; Romero P; Hu HM; Alvord WG; Smith JW; Fox BA; Urba WJ
    Clin Cancer Res; 2004 Jan; 10(2):668-80. PubMed ID: 14760090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells.
    Park JY; Jin DH; Lee CM; Jang MJ; Lee SY; Shin HS; Chung YH; Kim KY; Kim SS; Lee WB; Shin YK; Lee WJ; Park YM; Kim D
    J Immunother; 2010 Jun; 33(5):510-22. PubMed ID: 20463596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AE37 peptide vaccination in prostate cancer: identification of biomarkers in the context of prognosis and prediction.
    Perez SA; Anastasopoulou EA; Papamichail M; Baxevanis CN
    Cancer Immunol Immunother; 2014 Nov; 63(11):1141-50. PubMed ID: 25052849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial.
    Schuhmacher J; Heidu S; Balchen T; Richardson JR; Schmeltz C; Sonne J; Schweiker J; Rammensee HG; Thor Straten P; Røder MA; Brasso K; Gouttefangeas C
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33184050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human Asymptomatic Epitopes Identified from the Herpes Simplex Virus Tegument Protein VP13/14 (UL47) Preferentially Recall Polyfunctional Effector Memory CD44high CD62Llow CD8+ TEM Cells and Protect Humanized HLA-A*02:01 Transgenic Mice against Ocular Herpesvirus Infection.
    Srivastava R; Khan AA; Garg S; Syed SA; Furness JN; Vahed H; Pham T; Yu HT; Nesburn AB; BenMohamed L
    J Virol; 2017 Jan; 91(2):. PubMed ID: 27847359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
    Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
    Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
    Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG
    Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.